Jl. Zambrana et al., Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia, J HEART LUN, 17(12), 1998, pp. 1213-1219
Background: Oxidized low-density lipoprotein plays an important role in the
development of atherosclerosis. We evaluated the effect of two lipid-lower
ing drugs, bezafibrate and lovastatin, on the susceptibility of low-density
lipoproteins for oxidation in vitro in 21 heart transplant recipients with
hyperlipidemia.
Methods: Patients were given the same diet for 3 months, and after that the
y were randomized to lovastatin or bezafibrate for a period of 8 weeks and
then crossed over to an additional 8 weeks of either bezafibrate or lovasta
tin. Baseline parameters were also compared with those of a control group o
f healthy subjects and after both periods of pharmacologic treatment.
Results: The low-density lipoproteins of transplant recipients presents a s
horter lag time than in central subjects (64 +/- 3 vs 80 +/- 4 minutes, res
pectively). This parameter increases after both bezafibrate and lovastatin
treatment (83 +/- 5 and 80 +/- 4 minutes, respectively). Moreover, we did o
bserve a negative correlation between insulinemia and the lag time of oxida
tion after bezafibrate treatment (r = -0.5014, P <.021) and between the pol
yunsaturated fatty acids/monounsaturated fatty acids ratio in low-density l
ipoprotein cholesterol esters and lag time after lovastatin treatment (r =
-0.4631, P <.04).
Conclusions: Bezafibrate and lovastatin decrease the oxidizability of low-d
ensity lipoproteins in heart transplant recipients with hyperlipemia.